Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

GlaxoSmithKline Buys Back 1.3 Million Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 06:28pm CEST

GlaxoSmithKline PLC (>> GlaxoSmithKline plc) said Friday it has purchased 1,300,000 ordinary shares to be held in treasury.

MAIN FACTS:

-Highest price paid: 1455 pence per share.

-Lowest price paid: 1425 pence per share.

-Shares at 1610 GMT down 1%, at 1427 pence, valuing the company at GBP72 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; [email protected]

Stocks mentioned in the article : GlaxoSmithKline plc, GlaxoSmithKline plc
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 0.39% 1500 Delayed Quote.13.42%
GLAXOSMITHKLINE -0.60% 16.99 Delayed Quote.13.26%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
05/25GLAXOSMITHKLINE : Studies Conducted at GlaxoSmithKline plc on Chronic Obstructiv..
AQ
05/25FINDINGS FROM GLAXOSMITHKLINE PLC YI : ...
AQ
05/25GLAXOSMITHKLINE : Studies from GlaxoSmithKline plc Provide New Data on Lupus (Qu..
AQ
05/25GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Provide Details of New St..
AQ
05/25GLAXOSMITHKLINE : veteran Zhi Hong launches Brii Biosciences with $260M
AQ
05/24GLAXOSMITHKLINE : Chinese newco Brii launches with $260M
AQ
05/24GLAXOSMITHKLINE : EGX imposed LE10,000 fines on four listed companies
AQ
05/24GLAXOSMITHKLINE : GSK May Look at Merger Options for Indian Unit -The Economic T..
DJ
05/23Why the world needs more than one Ebola vaccine
RE
05/22ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/..
AQ
More news
News from SeekingAlpha
05/25Eidos Therapeutics files for initial public offering 
05/25Kezar Life Sciences on deck for IPO 
05/24TOP WALL STREET HEALTHCARE GAINERS F : Allergan, CVS Health, Patterson, Sanofi, .. 
05/24GILEAD : Novartis's Kymriah Is Coming To America 
05/23High Rates And Inflation Could Pose A Systemic Risk To Biotech 
Financials ( GBP)
Sales 2018 29 826 M
EBIT 2018 8 109 M
Net income 2018 3 804 M
Debt 2018 18 280 M
Yield 2018 5,33%
P/E ratio 2018 19,32
P/E ratio 2019 16,26
EV / Sales 2018 3,11x
EV / Sales 2019 2,99x
Capitalization 74 390 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 15,5  GBP
Spread / Average Target 3,6%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE13.42%98 990
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708
MERCK AND COMPANY5.01%158 970